{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T21:01:33Z","timestamp":1794085293053,"version":"4.8.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100007075","name":"European Society for Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.annonc.2021.08.1995","type":"journal-article","created":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T03:58:38Z","timestamp":1630900718000},"page":"1520-1536","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":490,"title":["Bone sarcomas: ESMO\u2013EURACAN\u2013GENTURIS\u2013ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up"],"prefix":"10.1016","volume":"32","author":[{"given":"S.J.","family":"Strauss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Frezza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Abecassis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bajpai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Biagini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bielack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.Y.","family":"Blay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bolle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bonvalot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Boukovinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.V.M.G.","family":"Bovee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Boye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Brodowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Buonadonna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"de \u00c1lava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.P.","family":"Dei Tos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Garcia del Muro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Dufresne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Fagioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Fedenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Ferraresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Gaspar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gasperoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Gelderblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Gouin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Grignani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gronchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.B.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hecker-Nolting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Hindi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Hohenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Joensuu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.L.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Jungels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Jutte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Kager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Kasper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Kopeckova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.A.","family":"Kr\u00e1korov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Le Cesne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Le Grange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Legius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Leithner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"L\u00f3pez Pousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Martin-Broto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Merimsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Messiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.B.","family":"Miah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Mir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Montemurro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Morland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Morosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Palmerini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Pantaleo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Piana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Piperno-Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Reichardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Rutkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.A.","family":"Safwat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Sangalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Sbaraglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Scheipl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Sch\u00f6ffski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sleijfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Sundby Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Trama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Unk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.J.","family":"van de Sande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.T.A.","family":"van der Graaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.J.","family":"van Houdt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Frebourg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Ladenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.G.","family":"Casali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Stacchiotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.annonc.2021.08.1995_bib1","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/S1470-2045(17)30445-X","article-title":"Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study","volume":"18","author":"Gatta","year":"2017","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2021.08.1995_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0246958","article-title":"Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network","volume":"16","author":"de Pinieux","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.annonc.2021.08.1995_bib3","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/00003086-200204000-00007","article-title":"Etiology of osteosarcoma","volume":"397","author":"Fuchs","year":"2002","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.annonc.2021.08.1995_bib4","series-title":"Soft Tissue and Bone Tumours","year":"2020"},{"key":"10.1016\/j.annonc.2021.08.1995_bib5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.humpath.2019.05.001","article-title":"EWSR1\/FUS-NFATc2 rearranged round cell sarcoma: clinicopathological series of 4 cases and literature review","volume":"90","author":"Diaz-Perez","year":"2019","journal-title":"Hum Pathol"},{"issue":"7","key":"10.1016\/j.annonc.2021.08.1995_bib6","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1097\/PAS.0000000000000846","article-title":"Sarcomas with CIC-rearrangements are a distinct pathologic entity with aggressive outcome: a clinicopathologic and molecular study of 115 cases","volume":"41","author":"Antonescu","year":"2017","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1016\/j.annonc.2021.08.1995_bib7","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/PAS.0000000000000965","article-title":"BCOR-CCNB3 fusion positive sarcomas: a clinicopathologic and molecular analysis of 36 cases with comparison to morphologic spectrum and clinical behavior of other round cell sarcomas","volume":"42","author":"Kao","year":"2018","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"10.1016\/j.annonc.2021.08.1995_bib8","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1097\/PAS.0000000000000629","article-title":"Recurrent BCOR internal tandem duplication and YWHAE-NUTM2B fusions in soft tissue undifferentiated round cell sarcoma of infancy: overlapping genetic features with clear cell sarcoma of kidney","volume":"40","author":"Kao","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"10.1016\/j.annonc.2021.08.1995_bib9","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.annonc.2021.07.006","article-title":"Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Gronchi","year":"2021","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2021.08.1995_bib10","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/CCO.0000000000000502","article-title":"Chordoma: update on disease, epidemiology, biology and medical therapies","volume":"31","author":"Frezza","year":"2019","journal-title":"Curr Opin Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2021.08.1995_bib11","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.path.2017.04.013","article-title":"Soft tissue tumors rarely presenting primary in bone; diagnostic pitfalls","volume":"10","author":"Sbaraglia","year":"2017","journal-title":"Surg Pathol Clin"},{"issue":"11","key":"10.1016\/j.annonc.2021.08.1995_bib12","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1093\/annonc\/mdx484","article-title":"Improved survival using specialized multidisciplinary board in sarcoma patients","volume":"28","author":"Blay","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2021.08.1995_bib13","author":"Bovee"},{"issue":"7","key":"10.1016\/j.annonc.2021.08.1995_bib14","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/1097-0142(19851001)56:7<1515::AID-CNCR2820560707>3.0.CO;2-6","article-title":"Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor","volume":"56","author":"Picci","year":"1985","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.annonc.2021.08.1995_bib15","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1302\/0301-620X.98B8.37346","article-title":"Ewing's sarcoma: only patients with 100% of necrosis after chemotherapy should be classified as having a good response","volume":"98-B","author":"Albergo","year":"2016","journal-title":"Bone Joint J"},{"key":"10.1016\/j.annonc.2021.08.1995_bib16","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1080\/17453674.1997.11744718","article-title":"Tumour necrosis and prognosis in Ewing's sarcoma","volume":"273","author":"Akerman","year":"1997","journal-title":"Acta Orthop Scand Suppl"},{"issue":"7","key":"10.1016\/j.annonc.2021.08.1995_bib17","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.ejso.2021.02.009","article-title":"Histological response to neoadjuvant chemotherapy in localized Ewing sarcoma of the bone: a retrospective analysis of available scoring tools","volume":"47","author":"Righi","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.annonc.2021.08.1995_bib18","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/00003086-198011000-00013","article-title":"A\u00a0system for the surgical staging of musculoskeletal sarcoma","volume":"153","author":"Enneking","year":"1980","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.annonc.2021.08.1995_bib19","series-title":"AJCC Cancer Staging Manual","year":"2017"},{"key":"10.1016\/j.annonc.2021.08.1995_bib20","series-title":"TNM Classification of Malignant Tumours","year":"2016"},{"key":"10.1016\/j.annonc.2021.08.1995_bib21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.humpath.2019.05.009","article-title":"Parosteal osteosarcoma: a monocentric retrospective analysis of 195 patients","volume":"91","author":"Ruengwanichayakun","year":"2019","journal-title":"Hum Pathol"},{"issue":"2","key":"10.1016\/j.annonc.2021.08.1995_bib22","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1365-2559.2011.04023.x","article-title":"Frequency of Mouse Double Minute 2 (MDM2) and Mouse Double Minute 4 (MDM4) amplification in parosteal and conventional osteosarcoma subtypes","volume":"60","author":"Duhamel","year":"2012","journal-title":"Histopathology"},{"key":"10.1016\/j.annonc.2021.08.1995_bib23","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejca.2018.11.027","article-title":"Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort","volume":"109","author":"Smeland","year":"2019","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.annonc.2021.08.1995_bib24","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/S1470-2045(16)30214-5","article-title":"Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial","volume":"17","author":"Marina","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2021.08.1995_bib25","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/annonc\/mdu526","article-title":"EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment","volume":"26","author":"Whelan","year":"2015","journal-title":"Ann Oncol"},{"issue":"34","key":"10.1016\/j.annonc.2021.08.1995_bib26","doi-asserted-by":"crossref","first-page":"8845","DOI":"10.1200\/JCO.2004.00.5785","article-title":"Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups","volume":"23","author":"Ferrari","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.08.1995_bib27","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejca.2017.08.013","article-title":"Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen \u2018OGS-12\u2019","volume":"85","author":"Bajpai","year":"2017","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.annonc.2021.08.1995_bib28","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/ijc.32526","article-title":"Results of API-AI based regimen in osteosarcoma adult patients included in the French OS2006\/Sarcome-09 study","volume":"146","author":"Piperno-Neumann","year":"2020","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.1995_bib29","doi-asserted-by":"crossref","first-page":"30","DOI":"10.5301\/tj.5000696","article-title":"EURO-B.O.S.S.: a European study on chemotherapy in bone-sarcoma patients aged over 40: outcome in primary high-grade osteosarcoma","volume":"104","author":"Ferrari","year":"2018","journal-title":"Tumori"},{"issue":"20","key":"10.1016\/j.annonc.2021.08.1995_bib30","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1200\/JCO.2014.60.0734","volume":"33","author":"Bielack","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2021.08.1995_bib31","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/S1470-2045(16)30096-1","article-title":"Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial","volume":"17","author":"Piperno-Neumann","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2021.08.1995_bib32","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1200\/JCO.2008.14.0095","article-title":"Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival \u2013 a report from the Children's Oncology Group","volume":"26","author":"Meyers","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"10.1016\/j.annonc.2021.08.1995_bib33","doi-asserted-by":"crossref","first-page":"4522","DOI":"10.1002\/cncr.26037","article-title":"Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma","volume":"117","author":"Ciernik","year":"2011","journal-title":"Cancer"},{"issue":"18","key":"10.1016\/j.annonc.2021.08.1995_bib34","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1002\/cncr.27451","article-title":"Impact of carbon ion radiotherapy for unresectable osteosarcoma of the trunk","volume":"118","author":"Matsunobu","year":"2012","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.annonc.2021.08.1995_bib35","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.oraloncology.2007.03.001","article-title":"Craniofacial osteosarcoma experience of the cooperative German-Austrian-Swiss osteosarcoma study group","volume":"44","author":"Jasnau","year":"2008","journal-title":"Oral Oncol"},{"key":"10.1016\/j.annonc.2021.08.1995_bib36","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1471-2407-14-23","article-title":"Is [F-18]-fluorodeoxy-D-glucose positron emission tomography of value in the management of patients with craniofacial bone sarcomas undergoing neo-adjuvant treatment?","volume":"14","author":"Frezza","year":"2014","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.annonc.2021.08.1995_bib37","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1200\/JCO.2003.03.141","article-title":"Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival","volume":"21","author":"Ferrari","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"22","key":"10.1016\/j.annonc.2021.08.1995_bib38","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.1002\/cncr.24566","article-title":"Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group","volume":"115","author":"Chou","year":"2009","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.annonc.2021.08.1995_bib39","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1200\/JCO.2005.04.063","article-title":"Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS)","volume":"23","author":"Kempf-Bielack","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.08.1995_bib40","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ejca.2018.02.017","article-title":"Interventional radiology: role in the treatment of sarcomas","volume":"94","author":"de Baere","year":"2018","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.annonc.2021.08.1995_bib41","doi-asserted-by":"crossref","first-page":"e27792","DOI":"10.1002\/pbc.27792","article-title":"Is there a role for chemotherapy after local relapse in high-grade osteosarcoma?","volume":"66","author":"Palmerini","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.annonc.2021.08.1995_bib42","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12885-016-2312-3","article-title":"Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone","volume":"16","author":"Palmerini","year":"2016","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.annonc.2021.08.1995_bib43","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1470-2045(19)30825-3","article-title":"Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial","volume":"21","author":"Italiano","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.1995_bib44","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S1470-2045(18)30742-3","article-title":"Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study","volume":"20","author":"Duffaud","year":"2019","journal-title":"Lancet Oncol"},{"issue":"16","key":"10.1016\/j.annonc.2021.08.1995_bib45","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1200\/JCO.18.02374","article-title":"Randomized double-blind phase II study of regorafenib in patients with metastatic osteosarcoma","volume":"37","author":"Davis","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2021.08.1995_bib46","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1200\/JCO.2003.08.132","article-title":"Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols","volume":"21","author":"Kager","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.08.1995_bib47","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejca.2016.12.016","article-title":"Extraskeletal osteosarcoma: a European Musculoskeletal Oncology Society study on 266 patients","volume":"74","author":"Longhi","year":"2017","journal-title":"Eur J Cancer"},{"issue":"18","key":"10.1016\/j.annonc.2021.08.1995_bib48","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1016\/j.ejca.2005.04.052","article-title":"Periosteal osteosarcoma\u2013a European review of outcome","volume":"41","author":"Grimer","year":"2005","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.annonc.2021.08.1995_bib49","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1002\/pbc.25535","article-title":"Primary cutaneous and subcutaneous Ewing sarcoma","volume":"62","author":"Di Giannatale","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"10.1016\/j.annonc.2021.08.1995_bib50","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMra2028910","article-title":"Ewing's sarcoma","volume":"384","author":"Riggi","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.annonc.2021.08.1995_bib51","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/pbc.24406","article-title":"An evaluation of [F-18]-fluorodeoxy-D-glucose positron emission tomography, bone scan, and bone marrow aspiration\/biopsy as staging investigations in Ewing sarcoma","volume":"60","author":"Newman","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"17","key":"10.1016\/j.annonc.2021.08.1995_bib52","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1200\/JCO.2000.18.17.3108","article-title":"Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group","volume":"18","author":"Cotterill","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"issue":"34","key":"10.1016\/j.annonc.2021.08.1995_bib53","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1200\/JCO.19.00915","article-title":"High-dose chemotherapy compared with standard chemotherapy and lung radiation in Ewing Sarcoma with pulmonary metastases: results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008","volume":"37","author":"Dirksen","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2021.08.1995_bib54","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1200\/JCO.2009.23.3585","article-title":"Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma\/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial","volume":"28","author":"Le Deley","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2021.08.1995_bib55","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1200\/JCO.2009.24.5845","article-title":"Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group","volume":"28","author":"van Doorninck","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.1995_bib56","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S0360-3016(02)03797-5","article-title":"Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials","volume":"55","author":"Schuck","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"33","key":"10.1016\/j.annonc.2021.08.1995_bib57","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1200\/JCO.2011.41.5703","article-title":"Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group","volume":"30","author":"Womer","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"23","key":"10.1016\/j.annonc.2021.08.1995_bib58","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1200\/JCO.2013.54.4833","article-title":"Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial","volume":"32","author":"Le Deley","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 15","key":"10.1016\/j.annonc.2021.08.1995_bib59","doi-asserted-by":"crossref","first-page":"11500","DOI":"10.1200\/JCO.2020.38.15_suppl.11500","article-title":"Comparison of two chemotherapy regimens in Ewing sarcoma (ES): overall and subgroup results of the Euro Ewing 2012 randomized trial (EE2012)","volume":"38","author":"Brennan","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"31","key":"10.1016\/j.annonc.2021.08.1995_bib60","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1200\/JCO.2018.78.2516","article-title":"High-dose chemotherapy and blood autologous stem-cell rescue compared with standard chemotherapy in localized high-risk Ewing sarcoma: results of Euro-E.W.I.N.G.99 and Ewing-2008","volume":"36","author":"Whelan","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"30","key":"10.1016\/j.annonc.2021.08.1995_bib61","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1200\/JCO.2016.68.1858","article-title":"Assessment of imaging modalities and response metrics in Ewing sarcoma: correlation with survival","volume":"34","author":"Koshkin","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2021.08.1995_bib62","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/cncr.29065","article-title":"Comparative evaluation of local control strategies in localized Ewing sarcoma of bone: a report from the Children's Oncology Group","volume":"121","author":"DuBois","year":"2015","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.annonc.2021.08.1995_bib63","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.ijrobp.2005.05.036","article-title":"Radiotherapy in Ewing tumors of the vertebrae: treatment results and local relapse analysis of the CESS 81\/86 and EICESS 92 trials","volume":"63","author":"Schuck","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.annonc.2021.08.1995_bib64","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejca.2016.03.075","article-title":"Can postoperative radiotherapy be omitted in localised standard-risk Ewing sarcoma? An observational study of the Euro-E.W.I.N.G group","volume":"61","author":"Foulon","year":"2016","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.annonc.2021.08.1995_bib65","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/CORR.0000000000000962","article-title":"Which factors are associated with local control and survival of patients with localized pelvic Ewing's sarcoma? A retrospective analysis of data from the Euro-EWING99 trial","volume":"478","author":"Andreou","year":"2020","journal-title":"Clin Orthop Relat Res"},{"issue":"3","key":"10.1016\/j.annonc.2021.08.1995_bib66","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.ijrobp.2011.03.038","article-title":"Proton radiotherapy for pediatric Ewing's sarcoma: initial clinical outcomes","volume":"82","author":"Rombi","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.annonc.2021.08.1995_bib67","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/cncr.24740","article-title":"The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES)","volume":"116","author":"Haeusler","year":"2010","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.annonc.2021.08.1995_bib68","doi-asserted-by":"crossref","first-page":"4977","DOI":"10.21873\/anticanres.12816","article-title":"Whole lung irradiation in patients with osteosarcoma and Ewing sarcoma","volume":"38","author":"Ronchi","year":"2018","journal-title":"Anticancer Res"},{"issue":"4","key":"10.1016\/j.annonc.2021.08.1995_bib69","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/pbc.23040","article-title":"Risk of recurrence and survival after relapse in patients with Ewing sarcoma","volume":"57","author":"Stahl","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"10.1016\/j.annonc.2021.08.1995_bib70","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/pbc.21917","article-title":"Response to high-dose ifosfamide in patients with advanced\/recurrent Ewing sarcoma","volume":"52","author":"Ferrari","year":"2009","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"10.1016\/j.annonc.2021.08.1995_bib71","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/pbc.20719","article-title":"Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors","volume":"47","author":"Hunold","year":"2006","journal-title":"Pediatr Blood Cancer"},{"issue":"suppl 15","key":"10.1016\/j.annonc.2021.08.1995_bib72","doi-asserted-by":"crossref","first-page":"11502","DOI":"10.1200\/JCO.2020.38.15_suppl.11502","article-title":"Results of the second interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES)","volume":"38","author":"McCabe","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.1995_bib73","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s12885-020-6683-0","article-title":"Incidence and time trends of sarcoma (2000-2013): results from the French network of cancer registries (FRANCIM)","volume":"20","author":"Amadeo","year":"2020","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.annonc.2021.08.1995_bib74","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s11999-016-4779-2","article-title":"Survival in mesenchymal chondrosarcoma varies based on age and tumor location: a survival analysis of the SEER database","volume":"475","author":"Schneiderman","year":"2017","journal-title":"Clin Orthop Relat Res"},{"issue":"3","key":"10.1016\/j.annonc.2021.08.1995_bib75","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/path.2913","article-title":"IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours","volume":"224","author":"Amary","year":"2011","journal-title":"J\u00a0Pathol"},{"issue":"2","key":"10.1016\/j.annonc.2021.08.1995_bib76","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/gcc.20937","article-title":"Identification of a novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data","volume":"51","author":"Wang","year":"2012","journal-title":"Genes Chromosomes Cancer"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.1995_bib77","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1186\/s12885-018-4741-7","article-title":"Survival and prognostic factors in conventional central chondrosarcoma","volume":"18","author":"Fromm","year":"2018","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.annonc.2021.08.1995_bib78","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/jor.24463","article-title":"Survival and prognosis of chondrosarcoma subtypes: SEER database analysis","volume":"38","author":"Amer","year":"2020","journal-title":"J\u00a0Orthop Res"},{"key":"10.1016\/j.annonc.2021.08.1995_bib79","first-page":"CD010778","article-title":"Intralesional treatment versus wide resection for central low-grade chondrosarcoma of the long bones","volume":"3","author":"Dierselhuis","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.1995_bib80","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12891-019-2502-7","article-title":"Outcome of conservative and surgical treatment of enchondromas and atypical cartilaginous tumors of the long bones: retrospective analysis of 228 patients","volume":"20","author":"Omlor","year":"2019","journal-title":"BMC Musculoskelet Disord"},{"issue":"6","key":"10.1016\/j.annonc.2021.08.1995_bib81","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1227\/01.NEU.0000143330.30405.AA","article-title":"Radiotherapeutic factors in the management of cervical-basal chordomas and chondrosarcomas","volume":"55","author":"No\u00ebl","year":"2004","journal-title":"Neurosurgery"},{"issue":"3","key":"10.1016\/j.annonc.2021.08.1995_bib82","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ejca.2014.11.007","article-title":"Mesenchymal chondrosarcoma: prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society study","volume":"51","author":"Frezza","year":"2015","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.annonc.2021.08.1995_bib83","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1093\/annonc\/mdt374","article-title":"Advanced chondrosarcomas: role of chemotherapy and survival","volume":"24","author":"Italiano","year":"2013","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2021.08.1995_bib84","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1634\/theoncologist.2010-0265","article-title":"Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003","volume":"17","author":"Fox","year":"2012","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.annonc.2021.08.1995_bib85","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1200\/JCO.2017.75.1743","article-title":"Osteosarcoma, chondrosarcoma, and chordoma","volume":"36","author":"Whelan","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2021.08.1995_bib86","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/cncr.32515","article-title":"Results of a prospective phase 2 study of pazopanib in patients with surgically unresectable or metastatic chondrosarcoma","volume":"126","author":"Chow","year":"2020","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.annonc.2021.08.1995_bib87","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1016\/S1470-2045(14)71190-8","article-title":"Building a global consensus approach to chordoma: a position paper from the medical and patient community","volume":"16","author":"Stacchiotti","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2021.08.1995_bib88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2020.09.018","article-title":"Carbon ion radiotherapy for sacral chordoma: a retrospective nationwide multicentre study in Japan","volume":"154","author":"Demizu","year":"2020","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2021.08.1995_bib89","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/jso.23617","article-title":"Long-term results of phase II study of high dose photon\/proton radiotherapy in the management of spine chordomas, chondrosarcomas, and other sarcomas","volume":"110","author":"DeLaney","year":"2014","journal-title":"J\u00a0Surg Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2021.08.1995_bib90","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1093\/annonc\/mdx054","article-title":"Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group","volume":"28","author":"Stacchiotti","year":"2017","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2021.08.1995_bib91","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/ng.2814","article-title":"Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone","volume":"45","author":"Behjati","year":"2013","journal-title":"Nat Genet"},{"issue":"14","key":"10.1016\/j.annonc.2021.08.1995_bib92","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/j.ejca.2014.06.003","article-title":"Adjuvant treatment with zoledronic acid after extensive curettage for giant cell tumours of bone","volume":"50","author":"Gouin","year":"2014","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.annonc.2021.08.1995_bib93","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/S1470-2045(19)30663-1","article-title":"Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study","volume":"20","author":"Chawla","year":"2019","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2021.08.1995_bib94","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1097\/CORR.0000000000001285","article-title":"Is a short-course of preoperative denosumab as effective as prolonged therapy for giant cell tumor of bone?","volume":"478","author":"Hindiskere","year":"2020","journal-title":"Clin Orthop Relat Res"},{"issue":"9","key":"10.1016\/j.annonc.2021.08.1995_bib95","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.ejso.2018.03.020","article-title":"Denosumab treatment of inoperable or locally advanced giant cell tumor of bone \u2013 multicenter analysis outside clinical trial","volume":"44","author":"Rutkowski","year":"2018","journal-title":"Eur J Surg Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2021.08.1995_bib96","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1245\/s10434-015-4634-9","article-title":"Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone","volume":"22","author":"Rutkowski","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2021.08.1995_bib97","doi-asserted-by":"crossref","first-page":"e000663","DOI":"10.1136\/esmoopen-2019-000663","article-title":"Rechallenge of denosumab in jaw osteonecrosis of patients with unresectable giant cell tumour of bone: a case series analysis and literature review","volume":"5","author":"Raimondi","year":"2020","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.annonc.2021.08.1995_bib98","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ejca.2004.08.026","article-title":"Doxorubicin and cisplatin chemotherapy in high-grade spindle cell sarcomas of the bone, other than osteosarcoma or malignant fibrous histiocytoma: a European Osteosarcoma Intergroup Study","volume":"41","author":"Nooij","year":"2005","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.annonc.2021.08.1995_bib99","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1200\/JCO.1999.17.10.3260","article-title":"Neoadjuvant chemotherapy with doxorubicin and cisplatin in malignant fibrous histiocytoma of bone: a European Osteosarcoma Intergroup study","volume":"17","author":"Bramwell","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2021.08.1995_bib100","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1086\/321805","article-title":"Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients","volume":"33","author":"Dykewicz","year":"2001","journal-title":"Clin Infect Dis"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753421042800?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753421042800?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T06:07:43Z","timestamp":1760335663000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753421042800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":100,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0923753421042800"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2021.08.1995","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bone sarcomas: ESMO\u2013EURACAN\u2013GENTURIS\u2013ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2021.08.1995","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Society for Medical Oncology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}